Pressure is mounting on the UK government to address the crisis in its life sciences sector after a second pharmaceutical giant, Eli Lilly, paused a major project in London. This follows MSD’s high-profile cancellation of its £1bn research hub, indicating a clear and troubling trend of corporate withdrawal.
Eli Lilly has confirmed it will not sign the lease for its planned “gateway lab,” an incubator space for new drugs, until the commercial environment in the UK improves. This decision directly links the investment freeze to the ongoing dispute over drug pricing and market access.
The move reinforces the message delivered by Sanofi, which has cut its UK clinical trials by 50% and described the country as a “terrible place” for the industry. Together, the actions of MSD, Eli Lilly, and Sanofi represent a united front of dissatisfaction with the current policy landscape.
With multiple companies now publicly holding back investment, the government is in a difficult position. It is being forced to reconsider its stance on drug pricing and spending, with the threat of further disinvestment looming if it fails to produce a plan that satisfies the industry’s demands for a more competitive market.
